Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE013 (USA) (Dr. Clarke)
· consented 2022-11-17
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-11 (study day 11); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-04-22 (study day 143); relationship: Y
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-08-13 (study day 256); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-08-24 (study day 267); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 288); relationship: N
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-01-05 (study day 401); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.